Table 3.
BME lesions in 4 study groups.
| Lesion | CRMO 1
n = 26 |
JIA n = 51 |
OS n = 8 |
NA n = 88 |
||||
|---|---|---|---|---|---|---|---|---|
| Unilateral | Bilateral | Unilateral | Bilateral | Unilateral | Bilateral | Unilateral | Bilateral | |
| Mandibula | 4 (15.4%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Scapula, SCJ, ACJ | 1 (3.8%) | 1 (3.8%) | 1 (2.0%) | 0 | 0 | 0 | 0 | 0 |
| Clavicle | 2 (7.7%) | 1 (3.8%) | 0 | 1 (2.0%) | 0 | 0 | 0 | 0 |
| Humerus | 3 (11.5%) | 1 (3.8%) | 2 (3.9%) | 0 | 0 | 1 (12.5%) | 0 | 0 |
| Ulna | 0 | 1 (3.8%) | 0 | 1 (2.0%) | 0 | 0 | 0 | 0 |
| Radius | 2 (7.7%) | 1 (3.8%) | 0 | 2 (3.9%) | 0 | 0 | 0 | 0 |
| Hand and wrist | 0 | 2 (7.7%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pelvis | 2 (7.7%) | 1 (3.8%) | 4 (7.8%) | 5 (9.8%) | 1 (12.5%) | |||
| Patella | 1 (3.8%) | 1 (3.8%) | 1 (2.0%) | 0 | 0 | 0 | 0 | 0 |
| Femur | 3 (11.5%) | 10 (38.5%) | 6 (11.8%) | 12(23.5%) | 2 (25.0%) | 3 (37.5%) | 1 (1.1%) | 1 (1.1%) |
| Tibia | 4 (15.4%) | 12 (46.2%) | 1 (2.0%) | 6 (11.8%) | 2 (25.0%) | 2 (25.0%) | 4 (4.4%) | 0 |
| Fibula | 3 (11.5%) | 1 (3.8%) | 1 (2.0%) | 1 (2.0%) | 0 | 0 | 1 (1.1%) | 0 |
| Talus | 4 (15.4%) | 5 (19.2%) | 5 (9.8%) | 6 (11.8%) | 0 | 3 (37.5%) | 2 (2.2%) | 3 (3.3%) |
| Calcaneus | 5 (19.2%) | 3 (11.5%) | 1 (2.0%) | 6 (11.8%) | 1 (12.5%) | 2 (25.0%) | 1 (1.1%) | 2 (2.2%) |
| Midfoot | 3 (11.5%) | 4 (15.4%) | 3 (5.9%) | 7 (13.7%) | 0 | 2 (25.0%) | 1 (1.1%) | 1 (1.1%) |
| Metatarsal/s | 4 (15.4%) | 2 (7.7%) | 0 | 1 (2.0%) | 0 | 0 | 2 (2.2%) | 2 (2.2%) |
| Toes | 0 | 1 (3.8%) | 0 | 0 | 0 | 0 | 1 (1.1%) | 1 (1.1%) |
1 CRMO—chronic recurrent multifocal osteomyelitis; JIA—juvenile idiopathic arthritis; OS—JIA with CRMO overlapping syndrome; NA—non-specific arthropathy; n—number of patients; SCJ—sterno-clavicular joint; ACJ—acromio-clavicular joint.